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Successful challenge with the
fully human EGFR antibody
panitumumab following an
infusion reaction with the
chimeric EGFR antibody
cetuximab
Infusion reactions are serious complications associated with
modern antibody therapy. In order to reduce the incidence
and severity of such reactions, the newer generations of
monoclonal antibodies contain less or no mouse-specific protein
sequences. We describe the clinical course of a patient who
experienced an infusion reaction following the administration of
the chimeric epidermal growth factor receptor (EGFR) antibody
cetuximab and who was then successfully challenged with the
fully human EGFR antibody panitumumab.
A 39-year-old white male with metastatic colon cancer was
scheduled to receive cetuximab monotherapy as third-line
treatment. Despite premedication with dexamethasone,
clemastine and ranitidine the patient experienced an infusion
reaction with massive urticaria mainly in the face and agitation
5 min after cetuximab was started. The infusion was then
stopped and he recovered 30 min later following another
infusion with steroids and antihistamines. Ninety minutes
later, the cetuximab infusion was restarted with reduced
infusion rate but had to be stopped again 20 min later because
of progressive urticaria and agitation. No subsequent
cetuximab was given. Due to rapid tumor progression and lack
of therapeutic alternatives, the patient was planned to receive
panitumumab. For safety reasons, the patient was monitored
on the intensive care unit during the first and second infusions
with panitumumab. The patient was premedicated with
cetrizine. No infusion reaction occurred and the patient
Annals of Oncology letters to the editor
Volume 18 |No. 5 |May 2007 letters to the editor | 963
received in total six infusions of panitumumab 6 mg/kg i.v. >60
min every 2 weeks. Serum for antipanitumumab antibodies was
collected before the first panitumumab infusion and at week 7;
no antipanitumumab antibodies were detected.
To our knowledge, this is the first report of a patient with
documented hypersensitivity to the chimeric EGFR antibody
cetuximab who was then exposed to the fully human EGFR
antibody panitumumab. The patient experienced no infusion
reactions nor did the patient exhibit any symptoms indicative
of a potential allergic response to panitumumab. Cetuximab
has been associated with infusion reactions of any grade in
19% of patients (severe infusion reactions in 3% of
patients) [1]. Severe events were characterized by rapid onset
of airway obstruction, urticaria, hypotension and/or cardiac
arrest [1]. The majority of infusion reactions (90%) occurred
during the initial infusion despite antihistamine prophylaxis
[1]. Infusion reactions to panitumumab are very rare. In the
pivotal phase 3 trial of panitumumab plus best supportive care
(BSC) versus BSC alone, no grade 3 or 4 infusion reactions
occurred. One patient (<1%) had an infusion reaction (grade
2) to panitumumab and discontinued treatment (Peeters M,
Van Cutsem E, Siena S et al., submitted for publication) [2].
These data and our case report indicate that there may be
indeed differences in the hypersensitivity profile between anti-
EGFR antibodies. Further studies of panitumumab focusing on
infusion events in patients who are intolerant to cetuximab
are warranted.
D. Helbling* & M. Borner
Department of Medical Oncology, Clinic of Medical Oncology, University
Hospital Inselpital Bern, Freiburgstrasse, 3010 Bern, Switzerland
(*E-mail: daniel.helbling@insel.ch)
references
1. Erbitux (cetuximab) prescribing information. ImClone Systems, Inc. 2006.
2. Van Cutsem E, Peeters M, Siena S et al. Panitumumab significantly improves
progression-free survival in patients with metastatic colorectal cancer. Ann Oncol
2006; 17 (Suppl 6): vi27 (Abstr O-027).
doi:10.1093/annonc/mdm130
letters to the editor Annals of Oncology
964 | letters to the editor Volume 18 |No. 5 |May 2007
